<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04351893</url>
  </required_header>
  <id_info>
    <org_study_id>17-601-E</org_study_id>
    <nct_id>NCT04351893</nct_id>
  </id_info>
  <brief_title>Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology</brief_title>
  <acronym>CAUSE</acronym>
  <official_title>Craniofacial Microsomia: Accelerating Understanding of the Significance and Etiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Javeriana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Icesi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional Edgardo Rebagliati Martins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Investigaci√≥n Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Comfamiliar Risaralda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CAUSE study is a multicenter study, with domestic (n=4) and international (n=6) study
      sites. Children and young adults (ages 0-18) who have microtia and/or craniofacial microsomia
      and their parents are invited to participate. Children and parents are asked to provide a DNA
      sample (blood or saliva) and are asked to upload a few photos of their face. Parents are
      asked a short interview. Participants are able to participate from home or at one of four
      domestic sites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify Genetic Variants</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To identify genetic variants related to the CFM spectrum using whole genome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize phenotype</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To characterize the detailed phenotype in individuals with CFM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize markers</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To characterize ancestry markers in individuals with CFM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coding and non-coding variants</measure>
    <time_frame>Through study completion, an average of 1 year.</time_frame>
    <description>To assess coding and non-coding variants in selected candidate genes in individuals with CFM</description>
  </secondary_outcome>
  <enrollment type="Anticipated">883</enrollment>
  <condition>Microtia</condition>
  <condition>Microtia-Anotia</condition>
  <condition>Craniofacial Microsomia</condition>
  <condition>Goldenhar Syndrome</condition>
  <condition>OAVS</condition>
  <condition>OAV Syndrome</condition>
  <condition>Hemifacial Microsomia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Participants are asked for blood or saliva. If a participant is having a surgery, tissue that
      would otherwise be discarded would also be requested.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All CFM cases, their parents, and their relatives regardless of their sex, race, or
        ethnicity. The prospective case samples will likely be drawn from outpatient clinics and
        medical centers, as well as CFM-related social medial networks.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION:

        Cases:

          -  Participant with CFM is 0-18 years of age

          -  Participant has diagnosis of at least one of the following conditions:

               -  Microtia

               -  Anotia

               -  Facial asymmetry AND preauricular tag(s)

               -  Facial asymmetry AND facial tag(s)

               -  Facial asymmetry AND epibulbar dermoid

               -  Facial asymmetry AND macrostomia (i.e., lateral cleft)

               -  Preauricular tag AND epibulbar dermoid

               -  Preauricular tag AND macrostomia

               -  Facial Tag AND epibulbar dermoid

               -  Macrostomia AND epibulbar dermoid

          -  Participant's parent or legal guardian has provided written informed consent prior to
             enrollment into study (for participants younger than 18 years of age).

          -  Participant speaks a language in which they are eligible for consent at their
             enrolling site

        Parents:

          -  Parent participant is the biological parent of a case participant already eligible and
             participating in the CAUSE study. Non-genetic parents will be interviewed about their
             child's known prenatal and genetic family history but will not be asked to provide DNA
             or have facial photographs taken.

          -  Participant speaks a language in which they are eligible for consent at their
             enrolling site

        Other relatives:

          -  Other relatives participants, of any age, are related biologically to a case
             participant already eligible and participating in the CAUSE study from a multiplex
             family (multiple affected individuals with CFM).

          -  Participant speaks a language in which they are eligible for consent at their
             enrolling site

        EXCLUSION:

        Cases:

          -  Participant is diagnosed with a known syndrome that involves microtia and
             underdevelopment of the jaw (Townes-Brocks, Treacher-Collins, Branchiootorenal, Nager,
             or Miller syndromes).

          -  Participant has abnormal chromosome studies (karyotype).

          -  Participant has mandibular asymmetry due to deformational plagiocephaly or
             torticollis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniela Luquetti, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura P Stueckle, MPH</last_name>
    <phone>206-884-1254</phone>
    <email>laura.stueckle@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniela Luquetti, MD, PhD</last_name>
    <phone>206-884-5120</phone>
    <email>daniela.luquetti@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Alexis Johns, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Amelia Drake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE Study</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Leanne Magee, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAUSE</last_name>
      <phone>206-884-1254</phone>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Stueckle, MPH</last_name>
      <phone>206-884-1254</phone>
      <email>laura.stueckle@seattlechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Luquetti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie Heike, MS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Javeriana</name>
      <address>
        <city>Bogot√°</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Zaran</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICESI</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry Pachajo</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Javeriana</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Hurtad</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica Comfamiliar Risaralda</name>
      <address>
        <city>Pereira</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Liliana Porras Hurtad</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Edgardo Rebagliati Martins</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milagros M. Due√±as Roq</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Gen√©tica M√©dica y Molecular (INGEMM)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Daniel Lapunzina Ba</last_name>
      <email>CAUSEstudy@seattlechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Peru</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 11, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>Daniela Luquetti</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goldenhar Syndrome</mesh_term>
    <mesh_term>Congenital Microtia</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Investigators do not plan to share, as CFM is a rare disease and could be potentially identifiable.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

